[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-456221-105":59,"doc-detail-456221-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","plasma-p-tau217-performance-for-detection-of-alzheimers-disease-neuropathology-in-underrepresented-populations","Plasma p-tau217 Performance for Detection of Alzheimer’s Disease Neuropathology in Underrepresented Populations","","Accessible, non-invasive plasma blood biomarkers are needed to reduce disparities in dementia research, since Black and Latino Americans face higher dementia burden and remain underrepresented in Alzheimer’s disease (AD) clinical trials. This study evaluates plasma p-tau217 for detecting AD neuropathology among cognitively normal Black and Latino participants using PET imaging and Lumipulse assays, testing a published threshold and deriving an optimized cut-off to improve identification of amyloid-positive individuals.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/plasma-p-tau217-performance-for-detection-of-alzheimers-disease-neuropathology-in-underrepresented-populations/456221/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/plasma-p-tau217-performance-for-detection-of-alzheimers-disease-neuropathology-in-underrepresented-populations/456221.png","ImageObject",300,407,{"name":92,"@type":93},"Jasmine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-07","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"Why was plasma p-tau217 evaluated in this study?","Question",{"text":112,"@type":113},"The study addresses the underrepresentation of Black and Latino Americans in dementia research and the need for accessible, non-invasive blood biomarkers to improve detection and recruitment for AD clinical trials.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was plasma p-tau217 measured and what imaging was used?",{"text":117,"@type":113},"Plasma p-tau217 was measured using Fujirebio Lumipulse assays, and participants underwent PET imaging with amyloid-PiB and tau-flortaucipir.",{"name":119,"@type":110,"acceptedAnswer":120},"What thresholds were tested and what diagnostic performance did they show?",{"text":121,"@type":113},"A known threshold (≥0.186 pg/mL) identified only 10/69 participants, missing early AD neuropathology in most cognitively normal Black and Latino individuals, while an optimized threshold (≥0.118 pg/mL) achieved higher sensitivity for amyloid-positive status.",{"name":123,"@type":110,"acceptedAnswer":124},"What conclusion did the study reach about applying existing thresholds?",{"text":125,"@type":113},"Validated symptomatic-AD thresholds failed to detect early AD neuropathology in a subset of cognitively normal participants, indicating that optimized thresholds are required to better detect preclinical AD in Black/Latino individuals.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},456221,1790796649,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":14,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":24},2336478487870,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","DOI: 10. 1002/alz70856_105551  \nBIOMARKERS  \nPOSTER PRESENTATION  \nBIOMARKERS (NON-NEUROIMAGING)  \nPlasma p-tau217 Performance for Detection of Alzheimer’s Disease Neuropathology in Underrepresented Populations  \nYoav D Piura1  Christian Lachner 1 Joshua A Bornhorst2  Paula Aduen 1  \nAlicia Algeciras-Schimnich2  Daniel Figdore2 Leah Schecter 1  Neill R. Graff-Radford 1   \nGregory S Day 1  \n1 Mayo Clinic in Florida, Jacksonville, FL, USA  \n2 Mayo Clinic, Rochester, MN, USA  \nCorrespondence  \nYoav D Piura, Mayo Clinic in Florida, Jacksonville, FL, USA. [Email:](Email: piura.yoav@mayo.edu)[ piura.yoav@mayo.edu](Email: piura.yoav@mayo.edu)  \nAbstract  \nBackground: Black and Latino Americans experience a disparate dementia burden yet remain underrepresented in dementia research, including clinical trials designed to slow or prevent symptomatic Alzheimer’s disease (AD). Accessible and non-invasive AD blood biomarkers may improve identification and recruitment of underrepresented participants into AD clinical trials. There is a clear need to assess the performance of emergent plasmaAD biomarkers for the detection ofAD neuropathology in cognitively normal Black and Latino Americans.  \nMethod: Cognitively normal Black and Latino participants underwent cognitive evaluations and PET (amyloid-PiB, tau-flortaucipir) imaging at Mayo Clinic in Florida. Plasma p-tau217 was measured using Fujirebio Lumipulse assays. We evaluated the diagnostic performance of a p-tau217 threshold (≥0. 186 pg/mL) known to identify non-Hispanic White participants with cognitive impairment and “positive” amyloid PET scans (>25 Centiloids). Next, we derived an optimized threshold to identify participants with “positive” amyloid PET using Youden’s method.  \nResult: The cohort included 58 Black (55%) and 47 Latino-White (45%) well-educated (mean 16.1±2. 3 years) individuals, with mean age 64.7±8.8 years, and slight female bias (63%). Plasma p-tau217 concentrations increased with age (rho=0. 269, p = 0.004) and declined with MoCA scores (rho=-0. 225, p = 0.027). Sixty-nine participants completed amyloid-and tau-PET imaging. Plasma p-tau217 concentrations increased with amyloid- (rho=0. 254, p = 0.044) but not with tau-PET standardized uptake value ratio (rho=0. 127; p = 0. 334). p-tau217 concentrations were ≥0. 186 pg/mL in 10/69 participants (14%), including 3/3 amyloid-and tau-PET positive (A+T+) participants, 3/8 A+T-participants (sensitivity: 55%), and 4/58 A-T-participants (specificity 93%). An optimized p-tau217 threshold of ≥0. 118 pg/mL identified 10/11 A+T± participants (sensitivity 91%), and 16/58 A-T- participants (specificity 73%). In A-T- participants,  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2025 The Alzheimer’s Association. Alzheimer’s & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer’s Association.  \nAlzheimer’s Dement. 2025;21(Suppl. 2):e105551.  \n[https://doi.org/10.1002/alz70856_105551](https://doi.org/10.1002/alz70856_105551)  \nwi[leyonlinelibrary.com/journal/alz](leyonlinelibrary.com/journal/alz)  \n1of2  \nBIOMARKERS  \nestimated glomerular filtration rate was lower in participants with ‘false positive’elevations in plasma p-tau217 (mean difference: 67 vs 81 ml/min/1.73m2 , p = 0.004), emphasizing the need for caution when interpreting plasma p-tau217 concentrationsin patients with decreased kidney function.  \nConclusion: Plasma p-tau217 thresholds validated in participants with symptomatic AD (≥0.186 pg/mL) failed to identify early AD neuropathology in 5/8 cognitively normal Black and Latino participants. Optimized thresholds are required to improve detection of preclinical AD in Black/Latino individuals.","cbCaiciewYrOPRzQ","https://ap.wps.com/l/cbCaiciewYrOPRzQ","pdf",94924,"English","# Background\n# Method\n# Result\n# Conclusion","[{\"question\":\"Why was plasma p-tau217 evaluated in this study?\",\"answer\":\"The study addresses the underrepresentation of Black and Latino Americans in dementia research and the need for accessible, non-invasive blood biomarkers to improve detection and recruitment for AD clinical trials.\"},{\"question\":\"How was plasma p-tau217 measured and what imaging was used?\",\"answer\":\"Plasma p-tau217 was measured using Fujirebio Lumipulse assays, and participants underwent PET imaging with amyloid-PiB and tau-flortaucipir.\"},{\"question\":\"What thresholds were tested and what diagnostic performance did they show?\",\"answer\":\"A known threshold (≥0.186 pg/mL) identified only 10/69 participants, missing early AD neuropathology in most cognitively normal Black and Latino individuals, while an optimized threshold (≥0.118 pg/mL) achieved higher sensitivity for amyloid-positive status.\"},{\"question\":\"What conclusion did the study reach about applying existing thresholds?\",\"answer\":\"Validated symptomatic-AD thresholds failed to detect early AD neuropathology in a subset of cognitively normal participants, indicating that optimized thresholds are required to better detect preclinical AD in Black/Latino individuals.\"}]","Plasma p-tau217 Performance for Detection of Alzheimer’s Disease Neuropathology in Underrepresented Populations | PDF",1790745368]